CTLA4 and neoplasm: Monoclonal antibodies against CTLA-4, PD-1/PD-L1 are designed to reinvigorate exhausted T cells and restore immune-mediated elimination of malignant cells, a strategy that has highly successful against multiple tumor subtypes including NSCLC (13–19).